MRUS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
MRUS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Merus NV's share price for the quarter that ended in Sep. 2024 was $49.96. Merus NV's Shares Outstanding (EOP) for the quarter that ended in Sep. 2024 was 68.43 Mil. Therefore, Merus NV's market cap for the quarter that ended in Sep. 2024 was $3,418.60 Mil.
Merus NV's quarterly market cap increased from Mar. 2024 ($2,642.70 Mil) to Jun. 2024 ($4,014.86 Mil) but then declined from Jun. 2024 ($4,014.86 Mil) to Sep. 2024 ($3,418.60 Mil).
Merus NV's annual market cap declined from Dec. 2021 ($1,382.25 Mil) to Dec. 2022 ($716.42 Mil) but then increased from Dec. 2022 ($716.42 Mil) to Dec. 2023 ($1,590.21 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Merus NV's Enterprise Value for Today is $2,216.60 Mil.
The historical data trend for Merus NV's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Merus NV Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Market Cap | Get a 7-Day Free Trial | 406.66 | 554.00 | 1,382.25 | 716.42 | 1,590.21 |
Merus NV Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Market Cap | Get a 7-Day Free Trial | 1,361.25 | 1,590.21 | 2,642.70 | 4,014.86 | 3,418.60 |
For the Biotechnology subindustry, Merus NV's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Merus NV's Market Cap distribution charts can be found below:
* The bar in red indicates where Merus NV's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Merus NV's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
Market Cap (A: Dec. 2023 ) | = | Share Price (A: Dec. 2023 ) | * | Shares Outstanding (EOP) (A: Dec. 2023 ) |
= | $27.5 | * | 57.8259 | |
= | $1,590.21 |
Merus NV's Market Cap for the quarter that ended in Sep. 2024 is calculated as
Market Cap (Q: Sep. 2024 ) | = | Share Price (Q: Sep. 2024 ) | * | Shares Outstanding (EOP) (Q: Sep. 2024 ) |
= | $49.96 | * | 68.4268 | |
= | $3,418.60 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Merus NV (NAS:MRUS) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Thank you for viewing the detailed overview of Merus NV's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Harry Shuman | officer: Chief Accounting Officer | C/O MERUS N.V., VALELAAN 62, UTRECHT P7 3584 CM |
Peter B. Silverman | officer: EVP & General Counsel | C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584 CM |
Sven Ante Lundberg | director, officer: President, CEO & PFO | C/O CRISPR THERAPEUTICS AG, 200 SIDNEY STREET, CAMBRIDGE MA 02139 |
Biotechnology Value Fund L P | other: See Explanation of Responses | 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104 |
Kruif John De | officer: Chief Technology Officer | C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584 CM |
Paolo Pucci | director | C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803 |
Len Kanavy | director | C/O MERUS N.V., VALELAAN 62, UTRECHT P7 3584 CM |
Maxine Gowen | director | |
Anand Mehra | director | 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025 |
Victor Sandor | director | C/O ARRAY BIOPHARMA INC., 3200 WALNUT STREET, BOULDER CO 80301 |
Mark T Iwicki | director | 84 WATERFORD DRIVE, MARLBOROUGH MA 01752 |
Gregory D Perry | director | C/O IMMUNOGEN, INC., 830 WINTER ST., WALTHAM MA 02451 |
Geuijen Cecile A W | officer: SVP & Chief Scientific Officer | C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584CM |
Andrew Joe | officer: SVP, CMO | C/O MERUS N.V., VALELAAN 62, UTRECHT P7 3584 CM |
Mark Throsby | officer: EVP & Chief Scientific Officer | C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584 CM |
From GuruFocus
By Marketwired • 11-06-2024
By GlobeNewswire • 12-01-2024
By Marketwired • 06-03-2024
By GuruFocus News • 11-15-2024
By Marketwired • 11-05-2024
By Marketwired • 12-01-2024
By Marketwired • 08-01-2024
By Marketwired • 09-30-2024
By Marketwired • 05-30-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.